Michael Robert Martin is Chief Business Officer at Aurinia Pharmaceuticals Inc. (AUPH). They have made 12 open-market trades across 1 company since 2021, most recently 2023-03-02.
CIK 0001837647
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $155K since 2022, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AUPH | 259,162 | $4.3M |
Shares reported on the most recent Form 4, priced at the 2023-03-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUPH | BUY | 2022-11-07 | 2022-11-09 | $5.16 | $155K | -13.1% | -12.4% | +68.4% |
| AUPH | SELL | 2022-03-02 | 2022-03-04 | $12.01 | $116K | +2.7% | +15.7% | +2.9% |
| AUPH | SELL | 2021-11-09 | 2021-11-12 | $30.25 | $4.5M | -32.8% | -32.1% | -36.4% |
| AUPH | SELL | 2021-11-01 | 2021-11-03 | $31.64 | $1.4M | -12.8% | -39.7% | -43.1% |
| AUPH | SELL | 2021-09-20 | 2021-09-22 | $23.44 | $2.7M | -10.1% | +19.4% | -3.9% |
| AUPH | SELL | 2021-09-14 | 2021-09-16 | $21.78 | $958K | +15.0% | +2.0% | +2.9% |
| AUPH | SELL | 2021-09-10 | 2021-09-14 | $20.89 | $2.4M | +9.8% | -0.6% | -6.0% |
| AUPH | SELL | 2021-09-07 | 2021-09-08 | $18.10 | $136K | +10.1% | +1.7% | +6.4% |
| AUPH | SELL | 2021-08-26 | 2021-08-27 | $17.81 | $401K | +8.7% | +32.3% | +8.6% |
| AUPH | SELL | 2021-08-09 | 2021-08-10 | $16.01 | $160K | -9.8% | +27.9% | +107.0% |
| AUPH | SELL | 2021-07-28 | 2021-07-29 | $13.86 | $69K | +10.0% | +22.8% | +115.9% |
| AUPH | SELL | 2021-06-22 | 2021-06-23 | $13.76 | $69K | -13.2% | -19.3% | +61.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.